FY2027 Earnings Estimate for WST Issued By Zacks Research

West Pharmaceutical Services, Inc. (NYSE:WST) – Analysts at Zacks Research issued their FY2027 earnings estimates for West Pharmaceutical Services in a report issued on Thursday, March 6th. Zacks Research analyst I. Bandyopadhyay expects that the medical instruments supplier will post earnings of $8.18 per share for the year. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share.

Several other equities analysts have also commented on the stock. Wolfe Research began coverage on shares of West Pharmaceutical Services in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Citigroup started coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They issued a “buy” rating and a $400.00 target price for the company. Deutsche Bank Aktiengesellschaft raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price objective for the company in a report on Friday, February 14th. KeyCorp reduced their target price on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Finally, UBS Group upgraded shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and upped their target price for the stock from $350.00 to $390.00 in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus target price of $344.00.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $232.37 on Friday. The firm’s 50 day moving average is $299.44 and its 200 day moving average is $306.81. The company has a current ratio of 2.79, a quick ratio of 2.23 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $16.80 billion, a P/E ratio of 34.73, a PEG ratio of 6.74 and a beta of 1.09. West Pharmaceutical Services has a 12 month low of $197.01 and a 12 month high of $400.88.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, topping the consensus estimate of $1.75 by $0.07. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. The company had revenue of $748.80 million during the quarter, compared to the consensus estimate of $739.59 million.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 7th. Shareholders of record on Wednesday, April 30th will be paid a dividend of $0.21 per share. The ex-dividend date is Wednesday, April 30th. This represents a $0.84 dividend on an annualized basis and a yield of 0.36%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.56%.

Institutional Trading of West Pharmaceutical Services

Large investors have recently made changes to their positions in the company. Whipplewood Advisors LLC acquired a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $25,000. Retirement Wealth Solutions LLC purchased a new position in West Pharmaceutical Services in the fourth quarter worth $34,000. Centricity Wealth Management LLC purchased a new position in West Pharmaceutical Services in the fourth quarter worth $35,000. Cornerstone Planning Group LLC increased its position in shares of West Pharmaceutical Services by 57.1% in the fourth quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 40 shares in the last quarter. Finally, Brooklyn Investment Group purchased a new position in shares of West Pharmaceutical Services in the third quarter valued at $41,000. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.